• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FICLATUZUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • FICLATUZUMAB chembl:CHEMBL1743018 Antineoplastic

    Alternate Names:

    FICLATUZUMAB
    AV-299
    SCH-900105

    Drug Info:

    Drug Class Therapeutic Antibodies
    FDA Approval not approved
    Drug Class monoclonal antibody
    Drug Indications antineoplastic agent
    (3 More Sources)

    Publications:

    Patnaik et al., 2014, Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma., Br. J. Cancer
  • FICLATUZUMAB   HGF

    Interaction Score: 12.88

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name AV-299, SCH900105
    Novel drug target Novel Target
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

  • FICLATUZUMAB   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type multiple myeloma
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    24901237


    Sources:
    JAX-CKB

  • MyCancerGenome: FICLATUZUMAB

    • Version: 20-Jun-2017

    Alternate Names:
    AV-299 Development Name
    SCH900105 Development Name
    FICLATUZUMAB Generic Name

    Drug Info:
    Drug Class Therapeutic Antibodies

    Publications:

  • TdgClinicalTrial: FICLATUZUMAB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class monoclonal antibody
    FDA Approval not approved

    Publications:

  • JAX-CKB: Ficlatuzumab

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Patnaik et al., 2014, Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma., Br. J. Cancer

  • TTD: Ficlatuzumab

    • Version: 2020.06.01

    Alternate Names:
    D03UBW TTD Drug ID

    Drug Info:

    Publications:

  • TALC: FICLATUZUMAB

    • Version: 12-May-2016

    Alternate Names:
    FICLATUZUMAB Primary Drug Name
    FICLATUZUMAB Drug Generic Name
    AV-299 Drug Synonym

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1743018

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1743018

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21